Notice of Interim Results

RNS Number : 7118W

Alliance Pharma PLC

03 August 2009

 



For immediate release

3 August 2009

ALLIANCE PHARMA PLC

('Alliance' or 'the Company')

Notification of Interim Results

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2009 on Wednesday 9 September 2009.

A briefing for analysts will be held at 10.00am on the day of the results at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.

For further information: 

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Rebecca Skye Dietrich / Stasa Filiplic
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney

Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or licenses, the rights to 35 branded pharmaceutical products and continues to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in the treatment of dermatological conditions, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

NORILFEEDEILVIA